Cibus, Inc.
NASDAQ:CBUSBiotechnology
+$0.04 today
- Market cap
- $104.71M
- Beta
- 1.65
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.16
Volume 0.25M
Average 0.51M
CBUS Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Cibus, Inc.NASDAQ: CBUS
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $1.2M fell 26.7% year over year, behind the -18.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 7.5% from the prior quarter. Over 3 fiscal years it compounded at +56.9% a year.
Context
- Depreciation & amortization amounted to 162.8% of revenue in FY2025, up 1.8 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -26.7% toward the trailing-twelve-month pace of -18.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 5.92M USD
- Year-over-year change
- -13.6%
- 4-year CAGR
- +26.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.92M | -13.6% |
| FY2024 | 2024-12-31 | 6.86M | +46.2% |
| FY2023 | 2023-12-31 | 4.69M | +205.9% |
| FY2022 | 2022-12-31 | 1.53M | -34.4% |
| FY2021 | 2021-12-31 | 2.34M | — |
Depreciation & Amortization vs competitors
How CBUS compares with its peers on the latest reported figures
- CBUS's LTM Mar 2026 depreciation & amortization of $5.46M is the 2nd largest of the 10 companies compared; the peer median is $648K.
- Its year-over-year change of -18.2% is the 7th highest of 9, against a peer median of -2.4%.
- Depreciation & amortization amounts to 127.4% of revenue for CBUS, versus a peer median of 3.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.74M | -13.3% | +13.9% | 3.0% | |
CBUSCibus, Inc. | LTM Mar 2026 | $5.46M | -18.2% | +56.9% | 127.4% |
| LTM Mar 2026 | $1.74M | +3.4% | — | 44.2% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.21M | +8.3% | +36.2% | — |
| LTM Mar 2026 | $960K | -46.5% | +26.8% | — | |
| LTM Mar 2026 | $648K | +132.3% | +52.6% | — | |
| LTM Mar 2026 | $158K | +4.6% | +29.7% | — | |
| LTM Mar 2026 | $131K | -84.0% | -41.1% | — | |
| LTM Mar 2026 | $19.18K | -8.2% | +4.3% | 3.2% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding CBUS) | $648K | -2.4% | +26.8% | 3.2% | |
Competitors are the stored peer set for CBUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (29.2M) | (16.89M) | (267.63M) | (282.71M) | (127.09M) |
| Depreciation & Amortization | 2.34M | 1.53M | 4.69M | 6.86M | 5.92M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.09M | 4M | 16.09M | 10.75M | 8.19M |
| Change in Working Capital | 7.49M | (2.89M) | 961K | 383K | 2.32M |
| Accounts Receivables | 4.89M | 0 | 1.7M | (512K) | 538K |
| Inventory | 1.38M | 0 | 0 | 0 | 0 |
| Accounts Payables | (360K) | (229K) | 2K | (188K) | 720K |
| Other Working Capital | 1.58M | (2.66M) | (745K) | 1.08M | 1.06M |
| Other Non-Cash Items | (1.53M) | (5.12M) | 215.76M | 206.68M | 60.06M |
| Operating Cash Flow | (18.81M) | (19.36M) | (46.21M) | (58.04M) | (50.59M) |
| Capital Expenditures | (497K) | (1.52M) | (4.32M) | (808K) | (578K) |
| Acquisitions (Net) | 0 | 0 | 59.38M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 11.7M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 11.2M | (1.52M) | 55.06M | (808K) | (578K) |
| Debt Repayment | (364K) | (376K) | (194K) | (879K) | (1.11M) |
| Common Stock Issued | 4.38M | 11.54M | 18.76M | 43.9M | 47.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (274K) | (1.17M) | 1.76M | (2.43M) | (142K) |
| Financing Cash Flow | 3.74M | 9.99M | 20.32M | 40.6M | 46.65M |
| Effect of Forex Changes | 498K | 99K | 3K | (13K) | 11K |
| Net Change in Cash | (3.87M) | (10.9M) | 29.17M | (18.27M) | (4.51M) |
| Free Cash Flow | (19.31M) | (20.88M) | (50.53M) | (58.85M) | (51.17M) |
Cibus, Inc.
NASDAQ:CBUS
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.